miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage
biopharmaceutical company focused on the discovery and development
of RNA-targeted therapies, announced today that it will be
presenting preclinical data on two of its three clinical-stage
programs at upcoming scientific conferences. New preclinical data
on MRG-110 will be presented at the 2018 Wound Healing Society
(WHS) Annual Meeting being held April 25-29, 2018 in Charlotte, NC.
MRG-110 is currently in a Phase 1 clinical trial in collaboration
with Servier.
In addition, new preclinical data on MRG-201
investigating the anti-fibrotic effects of a microRNA-29 mimic in
the eye will be presented at the Association for Research in Vision
and Ophthalmology (ARVO) Annual Meeting. The Company plans to
initiate a Phase 2 clinical trial for MRG-201 in cutaneous fibrosis
in the second quarter of 2018. miRagen also plans to publicly
present preclinical data about microRNA mimics of the
miR-183/96/182 cluster and their potential impact on preventing
retinal degeneration and preserving photoreceptor function. The
meeting is being held April 29 - May 3, 2018 in Honolulu, HI.
2018 Wound Healing Society Annual
Meeting
Oral and Poster Presentation
DetailsTitle: Improved perfusion and
wound healing in healthy pigs with MRG-110, an Inhibitor of
microRNA-92A
- Oral session: Session K: Concurrent Oral
Abstracts II
- Date: Friday, April 27, 2018, 2:45 p.m. –
2:55 p.m. ET
- Location: Room 203B, Charlotte Convention
Center
- Poster session: WHS Poster Gala &
Awards
- Poster number: P.IRD4
- Date: Friday, April 27, 2018, 7:15 p.m. –
8:45 p.m. ET
- Location: Hall C1, Charlotte Convention
Center
MRG-110 is an inhibitor of microRNA-92, which has been shown in
preclinical studies to be a regulator of new blood vessel creation.
miRagen believes microRNA-92 inhibitors may accelerate and improve
healing and thus decrease complications of wounds in a variety of
settings.
For additional information, please visit the WHS Annual Meeting
website: www.woundheal.org
2018 Association for Research in Vision and
Ophthalmology Annual Meeting
Oral Presentation
DetailsTitle: Restoring miRNAs of the
miR-183/96/182 cluster results in target gene regulation and
ameliorates symptoms of retinal degeneration in a mouse model of
retinitis pigmentosa
- Oral session: Session 473: Signaling in
retinal degeneration
- Date: Wednesday, May 2, 2018, 3:30 p.m. –
5:15 p.m. HST
- Location: Room 315, Hawaii Convention
Center
microRNAs of the miR-183/96/182 cluster have been shown to play
an important role in the establishment and maintenance of
neurosensory cells, including photoreceptors and hair cells (cells
associated with hearing). Genetic ablation of the cluster in mice
recapitulates features of retinitis pigmentosa in humans, a disease
characterized by gradual loss of photoreceptors, resulting in
eventual blindness. miRagen has developed mimics corresponding to
each of the microRNAs in that cluster and is evaluating how
restoring microRNA function could be a therapeutic approach to
delaying or even preventing photoreceptor loss.
Poster Presentation
DetailsTitle: Inhibition of ocular
fibrosis with a miR-29b mimic
- Poster session: Session 489: Retina,
drugs
- Poster number: C0249
- Date: Wednesday, May 2, 2018, 3:30 p.m. –
5:15 p.m. HST
- Location: Exhibit Hall, Hawaii Convention
Center
MRG-201 is designed to mimic the activity of microRNA-29 and
decrease the expression of proteins that are involved in fibrous
scar formation. miRagen believes the results from its Phase 1
clinical trial of MRG-201 in induced cutaneous fibrosis, which
demonstrated the potential of the product candidate to reduce
fibroplasia in humans, may provide support for the therapeutic
approach in other pathological fibrotic conditions, including
ocular fibrosis.
For additional information, please visit the ARVO Annual Meeting
website: www.arvo.org
About miRagen Therapeutics, Inc.
miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical
company discovering and developing proprietary RNA-targeted
therapies with a specific focus on microRNAs and their role in
diseases where there is a high unmet medical need. miRagen has
three clinical stage product candidates, cobomarsen (MRG-106),
MRG-201, and MRG-110. miRagen’s clinical product candidate for the
treatment of certain cancers, cobomarsen, is an inhibitor of
microRNA-155, which is found at abnormally high levels in malignant
cells of several blood cancers, as well as certain cells involved
in inflammation. miRagen’s clinical product candidate for the
treatment of pathological fibrosis, MRG-201, is a replacement for
microRNA-29, which is found at abnormally low levels in a number of
pathological fibrotic conditions, including cutaneous, cardiac,
renal, hepatic, pulmonary and ocular fibrosis, as well as systemic
sclerosis. MRG-110, an inhibitor of microRNA-92, is being developed
under a license and collaboration agreement with Servier for the
treatment of heart failure and other ischemic disease. In addition
to these programs, miRagen is developing a pipeline of preclinical
product candidates. The goal of miRagen’s translational medicine
strategy is to progress rapidly to first-in-human studies once it
has established the pharmacokinetics, pharmacodynamic, safety and
manufacturability of the product candidate in preclinical studies.
For more information, please visit www.miragen.com.
For information on clinical trials please visit
www.clinicaltrials.gov.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, including statements regarding
miRagen’s strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management or the expected features of or potential indications
for miRagen’s product candidates are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation: that
miRagen has incurred losses since its inception, and anticipates
that it will continue to incur significant losses for the
foreseeable future; future financing activities may cause miRagen
to restrict its operations or require it to relinquish rights;
miRagen may fail to demonstrate safety and efficacy of its product
candidates; miRagen’s product candidates are unproven and may never
lead to marketable products; miRagen’s product candidates are based
on a relatively novel technology, which makes it difficult to
predict the time and cost of development and of subsequently
obtaining regulatory approval, if at all; miRagen’s product
candidates may cause undesirable side effects or have other
properties that could delay or prevent the regulatory approval; and
the results of miRagen’s clinical trials to date are not sufficient
to show safety and efficacy of miRagen’s product candidates and may
not be indicative of future clinical trial results.
miRagen has based these forward-looking statements largely on
its current expectations and projections about future events and
trends. These forward-looking statements are subject to a number of
risks, uncertainties and assumptions, including those described
under the heading “Risk Factors” in miRagen’s Annual Report on Form
10-K and subsequent periodic reports filed with the Securities and
Exchange Commission. Moreover, miRagen operates in a very
competitive and rapidly changing environment. New risks emerge from
time to time. It is not possible for its management to predict all
risks, nor can it assess the impact of all factors on its business
or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in
any forward-looking statements it may make. In light of these
risks, uncertainties and assumptions, the future events and trends
discussed in this press release may not occur and actual results
could differ materially and adversely from those anticipated or
implied in the forward-looking statements. miRagen undertakes no
obligation to revise or publicly release the results of any
revision to such forward-looking statements, except as required by
law. Given these risks and uncertainties, readers are cautioned not
to place undue reliance on such forward-looking statements. All
forward-looking statements are qualified in their entirety by this
cautionary statement.
Investor/Media
Contact:
Adam
Levy
Chief Business
Officer
(720)
407-4595
alevy@miragen.com
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From May 2023 to May 2024